<PAGE>
As filed with the Securities and Exchange Commission on November 13, 2000
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2000
AMGEN INC.
(Exact name of Registrant as specified in its charter)
Delaware 95-3540776
(State or other jurisdiction of 000-12477 (I.R.S. Employer
incorporation or organization) (Commission File No.) Identification No.)
__________________
One Amgen Center Drive
Thousand Oaks, California 91320-1799
(Address of Principal Executive Offices including Zip Code)
(805) 447-1000
(Registrant's Telephone Number, Including Area Code)
<PAGE>
Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
On November 8, 2000, the Registrant publicly disseminated a press release
updating the investment community on the Registrant's business and providing
certain financial guidance.
The foregoing description is qualified in its entirety by reference to the
following document, which is incorporated herein by reference: the Registrant's
Press Release dated November 8, 2000, a copy of which is attached hereto as
Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
99.1 Registrant's Press Release dated November 8, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: November 13, 2000 AMGEN INC.
By: /s/ Kathryn E. Falberg
_______________________________
Name: Kathryn E. Falberg
Title: Senior Vice President, Finance
and Corporate Development and
Chief Financial Officer
